Finance Watch: ADARx Raises $200m, Alltrna Garners $109m To Fund RNA Medicines
Kyverna Increased Series B By $60m To $145m
Private Company Edition: Recent venture capital mega-rounds of $100m or more include ADARx and Alltrna, which closed five days after CG Oncology brought in $105m. Also, Tisento launched with assets from Cyclerion and $81m in series A funding and Georgiamune raised a $75m series A round.
